ABIVAX (EPA:ABVX) | WebDisclosure

Basculer en Français

10064	Companies
205710	Keywords
135950	Articles
109062	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 08/13/2025 at 18:00, 7 months 9 days ago

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote
ABIVAX communique le nombre total de droits de vote et d'actions conformément à la réglementation en vigueur. Abivax se focalise sur le développement de traitements thérapeutiques pour les maladies inflammatoires chroniques

Droits De Vote Actions Abivax Traitements Thérapeutiques Maladies Inflammatoires
PRESS RELEASE

published on 08/13/2025 at 18:00, 7 months 9 days ago

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote
ABIVAX communique le nombre d'actions composant son capital social et le nombre total de droits de vote conformément aux dispositions réglementaires

Droits De Vote Capital Social Abivax Finance Réglementaire
BRIEF

published on 07/28/2025 at 22:20, 7 months 25 days ago

Abivax conclut une offre publique de 747,5 millions de dollars

Biotechnologie Abivax Nasdaq Rectocolite Hémorragique Offre Publique
BRIEF

published on 07/28/2025 at 22:20, 7 months 25 days ago

Abivax Completes $747.5 Million Public Offering

Biotechnology Abivax Ulcerative Colitis Nasdaq Public Offer
PRESS RELEASE

published on 07/28/2025 at 22:15, 7 months 25 days ago

Abivax Announces Closing of $747.5 Million Public Offering
Abivax announces closing of $747.5 million public offering, enabling financing into Q4 2027 and reaching planned milestones for Ulcerative Colitis. ADSs listed on Euronext Paris and Nasdaq Global Market

Abivax Ulcerative Colitis Nasdaq Finance Public Offering
PRESS RELEASE

published on 07/28/2025 at 22:15, 7 months 25 days ago

Abivax annonce la réalisation de son offre au public de 747,5 millions de dollars
Abivax réalise une offre publique de 747,5 millions de dollars pour financer ses activités jusqu'en 2027. Cotée en bourse à Paris et Nasdaq, elle se concentre sur les maladies inflammatoires

Financement Abivax Bourse Offre Publique Maladies Inflammatoires
BRIEF

published on 07/25/2025 at 08:05, 7 months 29 days ago

Abivax Raises $747.5M Through ADS Offering

Biotechnology Abivax Nasdaq Capital Increase ADS Offering
BRIEF

published on 07/25/2025 at 08:05, 7 months 29 days ago

Abivax lève 747,5 millions de dollars grâce à une offre publique d'achat (ADS)

Biotechnologie Abivax Nasdaq Augmentation De Capital Offre ADS
PRESS RELEASE

published on 07/25/2025 at 08:00, 7 months 29 days ago

Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de livre associés, portant le produit brut de l'Offre à 747,5 M$ (637,5 M€)
Abivax annonce exercice intégral option souscription ADS supplémentaires. Produit brut Offre à 747,5 M$. Société biotechnologie spécialisée en immunothérapie. Prix offre 64,00$ par ADS. Actions admises Nasdaq et Euronext. Document relatif déposé auprès de la SEC

Biotechnologie Abivax SEC Immunothérapie Prix Offre
PRESS RELEASE

published on 07/25/2025 at 08:00, 7 months 29 days ago

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Abivax announces full exercise of underwriters’ option to purchase additional ADSs, bringing gross proceeds of offering to $747.5M (€637.5M). Company to apply net proceeds to identified use of funds

Abivax Underwriters ADSs Offering Proceeds

Accesswire

Published on 03/23/2026 at 11:30, 25 minutes ago

Trans Canada Gold Provides Update on Non-Brokered Private Placement and Flow-through Private Placement for Drilling at the Harrison Lake District Scale Gold Property Acquisition
Published on 03/23/2026 at 08:00, 3 hours 55 minutes ago

ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
Published on 03/23/2026 at 02:00, 9 hours 55 minutes ago

FutureGen Industries Announces Open Market Investments
Published on 03/20/2026 at 23:00, 2 days 12 hours ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 2 days 14 hours ago

Sky Gold Sets Options

View all ACCESSWIRE

EQS Group

Published on 03/23/2026 at 11:44, 11 minutes ago

Viromed Medical AG receives funding approval from the Federal Ministry of Research, Technology and Space for the development of cold plasma technology
Published on 03/23/2026 at 11:30, 25 minutes ago

EQS Group lance un module de gestion des risques pour faciliter la surveillance continue des risques liées aux données et à l’IA
Published on 03/23/2026 at 11:06, 48 minutes ago

Aroundtown SA: Release of a capital market information
Published on 03/23/2026 at 11:05, 50 minutes ago

ASUS Unveils Complete Portfolio Support for Intel® Core™ 200S Series
Published on 03/23/2026 at 11:05, 50 minutes ago

BRAIN Biotech has been granted a key patent for its CRISPR-BMC genome-editing technology

Les Echos

Published on 03/23/2026 at 08:10, 3 hours 45 minutes ago

Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 16 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 16 hours ago

AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 17 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 17 hours ago

Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA

View all LES ECHOS COMFI WIRE